Xealth, the US-based developer of a prescription platform for digital medicine, has secured $11m in a series A round that included several corporate investors.
Medical product distributor McKesson took part in the round through its McKesson Ventures unit, joining pharmaceutical firm Novartis, electronics and medical technology producer Philips and medical device maker ResMed.
Providence Ventures, the venture capital affiliate of healthcare system Providence St. Joseph, also took part, as did care provider UPMC; VC firm Threshold Ventures; and the partnership between hospital Froedtert and the Medical College of Wisconsin.
Xealth has created a platform that can integrate with healthcare providers’ existing software, helping them to monitor and prescribe digital care treatments such as apps, devices or online content.
The startup was incubated at Providence St. Joseph Health in 2017 and it is supplying the technology to UPMC and Froedtert and the Medical College of Wisconsin health network among other care providers.
The series A round comes after Xealth raised $8.5m in seed capital from Providence Ventures, UPMC, Froedtert Medical College of Wisconsin Health Network and Threshold Ventures (then known as DFJ Venture) in 2017.
